← FDA DRUG APPROVALS

FDA ANDA · ANDA079069

STAVUDINE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA079069
TYPE
ANDA
ORIGINAL APPROVAL
2008-12-29
LATEST ACTION
2020-12-02
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

STAVUDINEDiscontinued
STAVUDINE 30MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 15MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 40MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 20MG · CAPSULE · ORAL

Approval history

2020-12-02Labeling · Supplement 7 · standardAP
2020-12-02Labeling · Supplement 5 · standardAP
2012-03-09Labeling · Supplement 3AP
2011-08-01Labeling · Supplement 2AP
2011-04-07Labeling · Supplement 1AP
2008-12-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →